Figure 1

Antitumor activity of imatinib with or without chemotherapy in two human xenografted tumors. (A)(C). Both xenografted SCLC6 (A) and LY-3 (C) tumors were treated by etoposide (VP16) alone (E) at a dosage of 12 mg/kg in one daily intraperitoneal injection on days 1 to 3 (▲), etoposide (VP16) and STI571 (E + S) administered by one daily intraperitoneal injection at a dose of 70 mg/kg on days 1 to 3 (■), etoposide (VP16) and fluconazole (E + F) at a dosage of 40 mg/kg in one daily intraperitoneal injection on days 1 to 3 (○), or etoposide (VP16) with STI571 and fluconazole (E + S + F)(◇). All other groups included STI571 alone (S)(□), fluconazole alone (F)(△), and STI571 + fluconazole (S + F)(◆) and 0.9% NaCl (●). (B) Mice bearing LY-3 tumors were treated by one (□) daily intraperitoneal injection of STI571 (S) at a dose of 70 mg/kg from day 1 until sacrifice of the animals. (D) Xenografted LY-3 tumors were treated by gemcitabine at a dosage of 60 mg/kg by one weekly intraperitoneal injection, with (G + S)(■) or without (G)(▲) STI571 administered by one daily intraperitoneal injection at a dose of 70 mg/kg from day 1 until sacrifice of the animals. Mice treated by STI571 alone (S) are indicated by (□). All control groups received injections of 0.9% NaCl (Control)(●). Tumor growth was evaluated by measuring the relative tumor volume (RTV), as described in "Materials and Methods". A Mann-Whitney U test was used to assess the effects of treatments on xenografted tumor growth.